A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

Abstract Purpose Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as...

Full description

Bibliographic Details
Main Authors: Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, Yoshihito Ide, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Annals of Gastroenterological Surgery
Subjects:
capecitabine
irinotecan
neoadjuvant chemotherapy
oxaliplatin
rectal cancer
Online Access:https://doi.org/10.1002/ags3.12600

Internet

https://doi.org/10.1002/ags3.12600

Similar Items